Lab Tests to Monitor on GLP-1 Medications: What to Track and Why
Starting a GLP-1 medication like compounded semaglutide or tirzepatide is a meaningful step, and like any prescription treatment, it works best when paired with appropriate medical monitoring. Lab tes
In this article
Starting a GLP-1 medication like compounded semaglutide or tirzepatide is a meaningful step, and like any prescription treatment, it works best when paired with appropriate medical monitoring. Lab tests give both you and your provider a clear picture of how your body is responding, whether your metabolic markers are improving, and whether there is anything that warrants a conversation about your dose or plan.
*Compounded semaglutide and tirzepatide are not FDA-approved. This article is for educational purposes only and does not constitute medical advice. Lab monitoring recommendations vary based on individual health history. Always work with your licensed healthcare provider to determine which tests are appropriate for your specific situation. Individual results vary.*
---
This guide walks through the key lab tests that come up most often in the context of GLP-1 therapy, why each one matters, and what changes you might reasonably expect to see over time based on the available clinical research.
Why Lab Monitoring Matters During GLP-1 Treatment
GLP-1 receptor agonists work through multiple pathways in the body. They reduce appetite, slow gastric emptying, affect insulin and glucagon secretion, and have demonstrated effects on the cardiovascular system, liver, and kidneys. That broad mechanism of action is what makes them effective for weight management, and it is also why thoughtful monitoring covers several organ systems, not just body weight.
Lab tests serve two purposes during treatment. First, they help your provider identify any early signals that warrant attention, such as changes in kidney function during a period of gastrointestinal illness. Second, they help document the benefits you are getting, such as improvements in blood sugar, lipids, and liver enzymes, which can be motivating and help guide long-term treatment decisions.
The STEP 1 trial, which evaluated semaglutide 2.4 mg weekly in over 1,900 adults with obesity, reported significant improvements in cardiometabolic risk markers alongside weight loss, including reductions in HbA1c, blood pressure, triglycerides, and waist circumference [1]. Knowing what to look for helps you see the full picture of your progress.
Baseline Labs: Before You Start
Before beginning GLP-1 treatment, a baseline panel gives your provider a reference point. You cannot meaningfully track change without knowing where you started.
A typical baseline assessment includes a comprehensive metabolic panel (CMP), lipid panel, HbA1c, and kidney function markers. Some providers also order thyroid-stimulating hormone (TSH) and liver enzymes at baseline, particularly if there is a personal or family history of thyroid disease or liver conditions.
---
1. Blood Sugar and HbA1c
What it measures: Fasting glucose measures your blood sugar after an overnight fast. HbA1c (glycated hemoglobin) reflects your average blood sugar over the past 2-3 months.
Why it matters on GLP-1 therapy: GLP-1 receptor agonists stimulate insulin secretion in a glucose-dependent manner, meaning the effect is most active when blood sugar is already elevated. This makes them effective at lowering blood sugar with a relatively low risk of hypoglycemia on their own. If you are taking other diabetes medications alongside a GLP-1 medication, your provider may need to adjust dosing as blood sugar improves to avoid over-correction.
For people using GLP-1 medications primarily for weight management who do not have diabetes, blood sugar monitoring still provides useful information. Fasting glucose and HbA1c can reveal whether your insulin sensitivity is improving, which is one of the meaningful metabolic benefits of losing even a modest amount of weight.
When to test: At baseline, then at 3-month intervals in the first year of treatment, transitioning to 6-month intervals once stable. People with diabetes or prediabetes should follow their provider's specific schedule, which may be more frequent.
---
2. Lipid Panel
What it measures: Total cholesterol, LDL (low-density lipoprotein), HDL (high-density lipoprotein), and triglycerides.
Why it matters on GLP-1 therapy: Weight loss generally improves lipid profiles, and GLP-1 receptor agonists appear to contribute to this beyond weight loss alone. The SELECT cardiovascular outcomes trial, which studied semaglutide 2.4 mg in over 17,000 adults with obesity or overweight and established cardiovascular disease, demonstrated a 20% reduction in major adverse cardiovascular events [2]. While the full mechanisms include multiple factors, improvements in LDL and triglycerides are frequently observed in clinical studies.
In the STEP trials, semaglutide 2.4 mg was associated with meaningful reductions in triglycerides and non-HDL cholesterol, with more modest effects on LDL [1]. Triglyceride levels often show the earliest and most pronounced improvement, particularly in people who start with elevated values.
When to test: At baseline, then at 3 months, then annually if results are stable. If your lipids were abnormal at baseline, more frequent follow-up may be appropriate.
---
3. Kidney Function Tests
What it measures: Serum creatinine, estimated glomerular filtration rate (eGFR), and urine albumin-to-creatinine ratio (uACR). Together, these assess how well your kidneys are filtering waste.
Why it matters on GLP-1 therapy: There are two distinct considerations here: the kidney-protective effects of GLP-1 therapy over time, and the short-term dehydration risk during gastrointestinal illness.
On the protective side, longer-term data from the FLOW trial showed that semaglutide 1 mg reduced the risk of kidney disease progression and cardiovascular death in people with chronic kidney disease and type 2 diabetes. The mechanisms include reduced inflammation, lower blood pressure, and decreased albuminuria.
On the caution side, nausea and vomiting early in treatment can reduce fluid intake and increase dehydration risk, which puts temporary stress on kidney function. A pharmacovigilance analysis published in 2024 found that dehydration was among the most common adverse events contributing to serious outcomes in GLP-1 receptor agonist users, including semaglutide (25.1%) and tirzepatide (32.9%) [5]. A case report series found that GLP-1 agonist-associated acute kidney injury typically involved patients who had experienced significant gastrointestinal symptoms with inadequate fluid replacement [4].
This does not mean that kidney injury is common, but it does mean that staying well hydrated during periods of nausea or vomiting is clinically important. If you develop severe or prolonged GI symptoms, contact your provider rather than waiting for your next appointment.
When to test: At baseline, at 3 months, then at 6-12 month intervals depending on baseline kidney function. More frequent monitoring applies if you have pre-existing kidney disease.
---
4. Liver Enzymes
What it measures: ALT (alanine aminotransferase) and AST (aspartate aminotransferase), the primary markers of liver inflammation or damage.
Why it matters on GLP-1 therapy: Nonalcoholic fatty liver disease (NAFLD), now often called metabolic dysfunction-associated steatotic liver disease (MASLD), is extremely common in people with overweight or obesity, and many people are unaware they have it. GLP-1 receptor agonists have shown meaningful benefit in this area. A 2023 systematic review found that semaglutide treatment was associated with significant reductions in liver fat and liver enzyme levels (ALT and AST) in people with NAFLD or nonalcoholic steatohepatitis (NASH) [3].
Monitoring liver enzymes helps document this benefit and provides reassurance that the medication is not adversely affecting liver function.
When to test: At baseline, at 3-6 months, then annually. If liver enzymes were elevated at baseline, more frequent follow-up is appropriate to track normalization.
---
5. Thyroid-Stimulating Hormone (TSH)
What it measures: TSH reflects how hard the pituitary gland is working to stimulate the thyroid, serving as a sensitive indicator of thyroid function.
Why it matters on GLP-1 therapy: Animal studies showed GLP-1 receptor activation in thyroid C-cells in rodents, which led to a black box warning in the FDA prescribing information for GLP-1 medications regarding a possible association with thyroid tumors, specifically medullary thyroid carcinoma (MTC). Importantly, this association has not been confirmed in human clinical studies, and the actual risk in humans appears to be very low based on available evidence.
The practical implication is that GLP-1 medications are contraindicated in people with a personal or family history of MTC or multiple endocrine neoplasia type 2 (MEN2). For everyone else, TSH monitoring at baseline and at annual intervals is reasonable, particularly if you have a history of thyroid disease.
When to test: At baseline, then annually. Report any symptoms suggestive of thyroid disease (new neck mass, difficulty swallowing, hoarseness) to your provider promptly regardless of when your last test was.
---
6. Pancreatic Enzymes (Lipase)
What it measures: Lipase is an enzyme produced by the pancreas. Elevated levels can indicate pancreatic inflammation (pancreatitis).
Why it matters on GLP-1 therapy: GLP-1 receptor agonists carry a precaution regarding acute pancreatitis. Post-marketing data and early clinical trials showed a small number of pancreatitis cases in GLP-1 users, which prompted FDA label warnings. Subsequent large trials, including STEP and SELECT, did not demonstrate a statistically significant increase in pancreatitis risk compared to placebo, but the theoretical concern remains part of standard prescribing guidance.
Routine measurement of lipase is not required for all patients, but it is appropriate at baseline for people with a history of pancreatitis or gallstones. During treatment, if you develop severe and persistent abdominal pain (particularly pain that radiates to the back), this should prompt an urgent provider contact and evaluation including lipase measurement. Pancreatitis from GLP-1 medications, when it does occur, is more likely in people with existing risk factors.
When to test: At baseline if you have a history of pancreatitis or gallstones. During treatment, as clinically indicated based on symptoms.
---
7. Complete Metabolic Panel (CMP)
What it covers: The comprehensive metabolic panel bundles several tests together, including sodium, potassium, bicarbonate, blood urea nitrogen (BUN), creatinine, glucose, calcium, and liver enzymes (ALT, AST, alkaline phosphatase, bilirubin).
Why it matters on GLP-1 therapy: The CMP gives a useful broad view at baseline and at regular intervals. It covers kidney function, electrolytes, and liver markers in a single panel, making it an efficient monitoring tool. During the first months of treatment when GI side effects are most common, the electrolyte and kidney components of the CMP can flag any dehydration-related issues early.
When to test: At baseline and at 3-6 month intervals in the first year, then annually.
---
How Often Should You Get Lab Work Done?
There is no single universal schedule, because the right frequency depends on your starting health status, which other medications you take, and how your treatment is going. A general framework that many clinicians follow looks like this:
| Timing | Tests |
|---|---|
| Before starting | CMP, lipid panel, HbA1c, TSH (baseline) |
| 3 months | CMP, fasting glucose, HbA1c (if diabetic or prediabetic), lipid panel |
| 6 months | CMP, lipid panel |
| Annually | Full panel: CMP, lipid panel, HbA1c, TSH |
| As needed | Lipase (if abdominal symptoms); uACR (if kidney disease history) |
---
What to Bring to Your Provider Appointment
Coming prepared makes these conversations more productive. Before your appointment, it helps to:
- Have a printed or digital copy of your most recent lab results
- Note any symptoms you have experienced, including nausea, fatigue, changes in urine color or frequency, or abdominal pain
- Keep a brief record of your weight at home, if you track it
- Write down any other medications or supplements you started since your last visit
---
A Note on Compounded GLP-1 Medications
Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by licensed 503A compounding pharmacies based on individual patient prescriptions and are prescribed by licensed healthcare providers who are responsible for monitoring your care. The lab monitoring described in this article applies regardless of whether you are using a compounded or branded formulation; the same pathways and the same clinical considerations are at play.
If you have questions about your lab results or what monitoring schedule is right for you, your prescribing provider is the right first contact.
---
Summary
Lab monitoring during GLP-1 treatment covers several domains because GLP-1 medications have effects across multiple organ systems. The key areas to track are blood sugar (HbA1c and fasting glucose), lipids, kidney function (creatinine, eGFR, uACR), liver enzymes (ALT, AST), and thyroid function (TSH). Most people on GLP-1 therapy will see improvements in several of these markers alongside weight loss. Understanding what you are tracking, and why, helps you participate meaningfully in your own care.
---
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *N Engl J Med.* 2021;384(11):989-1002. [PMID: 33567185](https://pubmed.ncbi.nlm.nih.gov/33567185/)
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. *N Engl J Med.* 2023;389(24):2221-2232. [PMID: 37952131](https://pubmed.ncbi.nlm.nih.gov/37952131/)
- Bandyopadhyay S, et al. Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review. *World J Gastroenterol.* 2023;29(36):5186-5196. [PMID: 37717295](https://pubmed.ncbi.nlm.nih.gov/37717295/)
- Sharma T, et al. GLP-1 agonist associated acute kidney injury: A case report and review. *Diabetes Metab.* 2019;45(6):579-581. [PMID: 29275947](https://pubmed.ncbi.nlm.nih.gov/29275947/)
- He L, et al. Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events. *Front Endocrinol.* 2024;15:1414145. [PMID: 39040467](https://pubmed.ncbi.nlm.nih.gov/39040467/)
Stay informed
Weekly research updates and health guides. No spam.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. (2021).
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. (2023).
- Bandyopadhyay S, et al. Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review. World J Gastroenterol. (2023).
- Sharma T, et al. GLP-1 agonist associated acute kidney injury: A case report and review. Diabetes Metab. (2019).
- He L, et al. Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events. Front Endocrinol. (2024).
Ready to get started?
Check if you qualify for a personalized treatment plan.
Check Your Eligibility →
